Skanska has signed a $125m contract with Continuus Pharmaceuticals to build a manufacturing facility in Woburn, Massachusetts.
It sees Skanska renovating an existing shell, and raising its roof, to build a 4,500-sq-m factory inside in compliance with the US Food and Drug Administration’s Current Good Manufacturing Practice (CGMPs) specifications.
The factory will produce dry active pharmaceutical ingredients (API) and finished drug products in both sterile injectable and tablet forms.
Skanska said the facility is being developed to produce three critical care medicines and one additional “key drug with flexibility for future growth”.
The contract also includes a new third-floor penthouse and utility structure.
The shell’s existing roof will be raised to allow for additional equipment support areas and API manufacturing heights, as well as a new dunnage system installed over the existing roof, which will support the modular air handling unit penthouse.
Construction began in October 2021 and work is scheduled for completion in Q2 2022.